Achieves first quarter revenue growth of 4% as reported and 5% organic, supported by CAG Diagnostics recurring revenue growth of 3% as reported and 4.5% organic. Organic revenue growth supported by ...

IDEXX Laboratories (NASDAQ:IDXX) has outperformed the market over the past 10 years by 11.91% on an annualized basis producing an average annual return of 25.31%. Currently, IDEXX Laboratories has a ...

In the last year, many IDEXX Laboratories, Inc. (NASDAQ:IDXX) insiders sold a substantial stake in the company which may have sparked shareholders' attention. Knowing whether insiders are buying is ...

IDEXX Laboratories recently reported third-quarter 2025 earnings per share of $3.40, up over one-fifth year over year and ahead of expectations, while raising its full-year 2025 guidance for both ...

WESTBROOK, ME - JANUARY 4: IDEXX Laboratories has been added to the Standard & Poor's 500 Index. (Photo by Ben McCanna/Portland Portland Press Herald via Getty Images) IDEXX Laboratories’ (IDXX) ...

MEP Engineer: A/Z Corp. Located on a 25-acre site, the 114,000-sq-ft facility enhances the owner’s ability to research, develop and manufacture advanced veterinary diagnostic products, with capacity ...

IDEXX Laboratories, Inc. (NASDAQ:IDXX) Q3 2025 Earnings Call Transcript November 3, 2025 IDEXX Laboratories, Inc. beats earnings expectations. Reported EPS is $3.4, expectations were $3.14. Operator: ...

IDEXX Laboratories continues to outperform the S&P 500, driven by strong recurring revenue and a robust customer ecosystem. IDXX delivered a double beat in Q3, with revenue up 13% and EPS up 21%, ...

It notched a beat-and-raise third quarter. It cited innovation and increased customer take-up as reasons for the solid growth it posted during the frame. Idexx published its third-quarter figures well ...

Nov 3 (Reuters) - IDEXX Laboratories (IDXX.O), opens new tab raised its full-year profit and revenue forecasts on Monday and reported better third-quarter results than last year, as the pet ...